After researching more on Ibrutinib, I
have been able to find more information on Bruton’s Tyrosine Kinase (BTK) and the
mechanism of action of Ibrutinib. BTK is
found on all B cells and works as a relay of proteins in transmits signals like
a chain reaction to tell other cells to multiply, so it can become problematic
when BTK is expressed on leukemic B cells. In CLL cells, BTK is often over
expressed and can lead to an increase in the number of CLL cells and their
lifetimes. B-cell receptor (BCR) signaling is a chain of signals involving a
variety of molecules in order to carry out functions like cell growth and
differentiation, and is overly activated in CLL cells. Down the line of the BCR
signaling chain is BTK so inhibitors like Ibrutinib attach to BTK permanently
and hinder its signal transmitting function.
I had the chance to meet new patients in
Dr. Anwer’s clinic. One woman between the ages of 45 and 55 had a form of Acute
Lymphocytic Leukemia (ALL). A side effect of her leukemia was an unequal
distribution of upper body mass and lower body mass. The woman had a very thin
upper body, yet her legs were extremely swollen. On top of that, when her leg
was pressed with a finger, it would keep a finger imprint similar to pressing
down on a foam mattress.
I also had the privilege to meet with
patients who did not have leukemia themselves, yet were donating bone marrow
for leukemia patients. I soon realized how much the donors had to be
responsible for, such as their own diet and exercise routine to ensure their
bone marrow is healthy and that their post-donation recovery goes smoothly.
Thank you for taking time out of your
day to read my blog. Once again, if you have any questions, leave a comment
below. Have a great day.
No comments:
Post a Comment